CANY
IART icon

Caxton Associates (New York)’s Integra LifeSciences IART Stock Holding History

Caxton Associates (New York)’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,557
Closed -$235K – 521
2022
Q3 		$235K Buy
+5,557
New +$285K 0.03% 369

Other funds holding IART

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Caxton Associates (New York)'s IART Position: Q4 2022 in Review

Caxton Associates (New York) sold out of Integra LifeSciences (IART) in Q4 2022, closing a stake of 5,557 shares — an estimated $235K sold.

Caxton Associates (New York) first reported a position in IART in Q3 2022 and held it in 1 quarter. The position peaked at $235K in Q3 2022. 281 funds tracked by Wall St. Rank hold IART as of Q4 2022.

  • Caxton Associates (New York) reported no remaining Integra LifeSciences position as of Q4 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 5,557 Integra LifeSciences shares in Q4 2022, an estimated $235K.
  • Caxton Associates (New York) first reported a position in Integra LifeSciences in Q3 2022 and held it in 1 quarter.
  • Caxton Associates (New York)'s Integra LifeSciences position peaked at $235K in Q3 2022.
  • 281 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2022.

Based on Caxton Associates (New York)'s 13F filing for Q4 2022, filed 14 Feb 2023.